bafna pharmaceuticals has scheduled a meeting of its Board of Directors for Friday, May 29, 2026. The primary agenda of the meeting is to consider and approve the audited financial results of the company for the quarter and year ended March 31, 2026. This intimation is made pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In accordance with the company’s Code of Conduct for Prevention of Insider Trading, the trading window for dealing in shares by designated persons and their immediate relatives has been closed. This closure is effective from April 01, 2026, and will remain in place until May 31, 2026, inclusive of both dates. The measure is intended to ensure compliance during the period leading up to the financial results announcement.

The company has requested the stock exchanges to take the above information on record. The intimation was signed by Mohanachandran A, Company Secretary & Compliance Officer, on May 21, 2026.

Key Details

Bafna Pharmaceuticals Limited has issued a clarification to stock exchanges regarding significant movement in its share price, responding to queries received from both BSE and NSE on April 13, 2026.

Response to Exchange Queries

The Chennai-based pharmaceutical company addressed the concerns raised by the exchanges through formal communications. The company received queries from NSE (Reference No. NSE/CM/Surveillance/16817) and BSE (Reference No. L/SURV/ONL/PV/APJ/2026-2027/3719), both dated April 13, 2026, seeking clarification on the notable price movement in the company's shares.

Company's Position on Price Movement

In its response, Bafna Pharmaceuticals clarified that it is neither aware of nor has withheld any information or events that could have influenced the significant movement in its share price. The company emphasized that the price movement appears to be market-driven and can be attributed to general market conditions and prevailing investor sentiments.

The management specifically stated that neither the company nor its leadership has any connection with or control over the share price movements on stock exchange platforms. This clarification aims to address any speculation about undisclosed corporate developments that might have triggered the price volatility.

Regulatory Compliance Commitment

Bafna Pharmaceuticals reaffirmed its commitment to maintaining transparency and regulatory compliance. The company stated that it has complied and will continue to comply with all applicable disclosure requirements under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

The clarification was signed by Mohanachandran A, Company Secretary & Compliance Officer, and submitted to both exchanges on April 15, 2026. The company requested the exchanges to take the clarification on record, demonstrating its proactive approach to addressing regulatory queries and maintaining market transparency.